204 related articles for article (PubMed ID: 36915247)
41. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
43. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
[TBL] [Abstract][Full Text] [Related]
44. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
45. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
Bachet JB; Laurent-Puig P; Meurisse A; Bouché O; Mas L; Taly V; Cohen R; Gornet JM; Artru P; Louafi S; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Blons H; Vernerey D; Taieb J
Eur J Cancer; 2023 Aug; 189():112934. PubMed ID: 37390800
[TBL] [Abstract][Full Text] [Related]
46. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
47. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract][Full Text] [Related]
48. Ascites and Serial Plasma Circulating Tumor DNA for Predicting the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis.
Pu X; Li Z; Wang X; Jiang H
Front Oncol; 2022; 12():791418. PubMed ID: 35145914
[TBL] [Abstract][Full Text] [Related]
49. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
[TBL] [Abstract][Full Text] [Related]
50. Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.
Lee SB; Kim JW; Kim HG; Hwang SH; Kim KJ; Lee JH; Seo J; Kang M; Jung EH; Suh KJ; Kim SH; Kim JW; Kim YJ; Kim JH; Kwon NJ; Lee KW
Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38697850
[TBL] [Abstract][Full Text] [Related]
51. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
52. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
53. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
Wei C; Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
Br J Haematol; 2023 Jul; 202(1):86-95. PubMed ID: 37132364
[TBL] [Abstract][Full Text] [Related]
54. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
55. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
56. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
57. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
58. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
60. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
